In this course will be discuss :

- The performance of current screening programmes and their long-term outcomes.

- New diagnostic methods (eg genomics, proteomics, metabolomics) and their sensitivity and specificity in different populations.

- The evidence required to support the introduction of a new screening programme.

- To discuss the multidisciplinary management of neuroendocrine tumours.

- The ethics and health economics of screening.

- How to assess and refine screening programmes.

Target audience and participant profile are :

The target audience for this educational programme is clinical geneticists, metabolic physicians, paediatricians, neonatologists, lab scientists.

Registration deadline : 14th august 2026